Qing Wang1, Andrea De Luca1, Colette Smith1, Robert Zangerle1, Helen Sambatakou1, Fabrice Bonnet1, Colette Smit1, Philipp Schommers1, Alicia Thornton1, Juan Berenguer1, Lars Peters1, Vincenzo Spagnuolo1, Adriana Ammassari1, Andrea Antinori1, Eugenia Quiros-Roldan1, Cristina Mussini1, Jose M Miro1, Deborah Konopnicki1, Jan Fehr1, Maria A Campbell1, Monique Termote1, Heiner C Bucher1. 1. From Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, Basel, Switzerland; University of Siena, Siena, Italy; University College London, London, United Kingdom; Innsbruck Medical University, Innsbruck, Austria; University of Athens, Athens, Greece; Université Bordeaux, Bordeaux, France; Stichting HIV Monitoring, Amsterdam, the Netherlands; University Hospital of Cologne, Cologne, Germany; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Rigshospitalet, Copenhagen, Denmark; IRCCS Ospedale San Raffaele, Milan, Italy; National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy; University of Brescia, Brescia, Italy; University of Modena and Reggio Emilia, Modena, Italy; University of Barcelona, Barcelona, Spain; Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium; and University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Abstract
Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear. Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infected patients. Design: Cohort study. Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available. Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring. Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients. Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group. Conclusion: In HIV-infected patients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL. Primary Funding Source: European Union Seventh Framework Programme.
Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infectedpatients is unclear. Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infectedpatients. Design: Cohort study. Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Patients: HIV-infectedpatients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available. Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring. Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients. Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group. Conclusion: In HIV-infectedpatients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL. Primary Funding Source: European Union Seventh Framework Programme.
Authors: Leah Shepherd; Lene Ryom; Matthew Law; Camilla Ingrid Hatleberg; Stephane de Wit; Antonella d'Arminio Monforte; Manuel Battegay; Andrew Phillips; Fabrice Bonnet; Peter Reiss; Christian Pradier; Andrew Grulich; Caroline Sabin; Jens Lundgren; Amanda Mocroft Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Gordana Halec; Tim Waterboer; Nicole Brenner; Julia Butt; W David Hardy; Gypsyamber DʼSouza; Steven Wolinsky; Bernard J Macatangay; Michael Pawlita; Roger Detels; Otoniel Martínez-Maza; Shehnaz K Hussain Journal: J Acquir Immune Defic Syndr Date: 2019-03-01 Impact factor: 3.771
Authors: Sarah J Willis; H Nina Kim; Chad J Achenbach; Edward R Cachay; Katerina A Christopoulos; Heidi M Crane; Ricardo A Franco; Christopher B Hurt; Mari M Kitahata; Richard D Moore; Michael J Silverberg; Phyllis C Tien; Daniel Westreich; Julia L Marcus Journal: HIV Med Date: 2021-12-23 Impact factor: 3.094
Authors: Pierre Gantner; Laurent Cotte; Clotilde Allavena; Firouzé Bani-Sadr; Thomas Huleux; Claudine Duvivier; Marc-Antoine Valantin; Christine Jacomet; Véronique Joly; Antoine Chéret; Pascal Pugliese; Pierre Delobel; André Cabié; David Rey Journal: PLoS One Date: 2019-04-18 Impact factor: 3.240